Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
The FDA identified an estimated 9 excess GBS cases per million doses for Pfizer's Abrysvo and 7 excess cases per million for GSK's Arexvy. Updated warnings stem from Medicare-based studies ...
(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ... manufactured by Pfizer Inc. (PFE), and Arexvy ...
GlobalData on MSN4d
Pfizer’s colon cancer combo approval further supported by Phase III winPfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...
Also Read: Pfizer And GSK’s RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder Each year, around 100,000 individuals worldwide receive a diagnosis of high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback